63 related articles for article (PubMed ID: 38755613)
1. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data.
Rubahamya B; Dong S; Thurber GM
Sci Adv; 2024 May; 10(22):eadk1894. PubMed ID: 38820153
[TBL] [Abstract][Full Text] [Related]
2. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
[TBL] [Abstract][Full Text] [Related]
3. The relationship between tumor metabolism and 5-fluorouracil resistance.
Hu J; Li A; Guo Y; Ma T; Feng S
Biochem Pharmacol; 2023 Dec; 218():115902. PubMed ID: 37922975
[No Abstract] [Full Text] [Related]
4. ADCdb: the database of antibody-drug conjugates.
Shen L; Sun X; Chen Z; Guo Y; Shen Z; Song Y; Xin W; Ding H; Ma X; Xu W; Zhou W; Che J; Tan L; Chen L; Chen S; Dong X; Fang L; Zhu F
Nucleic Acids Res; 2024 Jan; 52(D1):D1097-D1109. PubMed ID: 37831118
[TBL] [Abstract][Full Text] [Related]
5. Multivalent protein-drug conjugates - An emerging strategy for the upgraded precision and efficiency of drug delivery to cancer cells.
Porębska N; Ciura K; Chorążewska A; Zakrzewska M; Otlewski J; Opaliński Ł
Biotechnol Adv; 2023 Oct; 67():108213. PubMed ID: 37453463
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.
Zhou W; Fang P; Yu D; Ren H; You M; Yin L; Mei F; Zhu H; Wang Z; Xu H; Cao Y; Sun X; Xu X; Bi J; Wang J; Ma L; Wang X; Chen L; Zhang Y; Cen X; Zhu X; Lou L; Liu D; Tan X; Yang J; Meng T; Shen J
Mol Cancer Ther; 2023 Aug; 22(8):913-925. PubMed ID: 37196158
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability.
Nguyen TD; Bordeau BM; Balthasar JP
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765668
[TBL] [Abstract][Full Text] [Related]
8. Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody-Drug Conjugates.
Bordeau BM; Nguyen TD; Polli JR; Chen P; Balthasar JP
Mol Cancer Ther; 2023 Apr; 22(4):459-470. PubMed ID: 36723609
[TBL] [Abstract][Full Text] [Related]
9. Minibody-Based and scFv-Based Antibody Fragment-Drug Conjugates Selectively Eliminate GD2-Positive Tumor Cells.
Kalinovsky DV; Kholodenko IV; Kibardin AV; Doronin II; Svirshchevskaya EV; Ryazantsev DY; Konovalova MV; Rozov FN; Larin SS; Deyev SM; Kholodenko RV
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674755
[TBL] [Abstract][Full Text] [Related]
10. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin.
Ma J; Xu X; Fu C; Xia P; Tian M; Zheng L; Chen K; Liu X; Li Y; Yu L; Zhu Q; Yu Y; Fan R; Jiang H; Li Z; Yang C; Xu C; Long Y; Wang J; Li Z
Biomater Res; 2022 Nov; 26(1):64. PubMed ID: 36435809
[TBL] [Abstract][Full Text] [Related]
11. Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthma.
Ma L; Zhu M; Li G; Gai J; Li Y; Gu H; Qiao P; Li X; Ji W; Zhao R; Wu Y; Wan Y
Respir Res; 2022 Nov; 23(1):316. PubMed ID: 36403040
[TBL] [Abstract][Full Text] [Related]
12. CD38-specific nanobodies allow
Pape LJ; Hambach J; Gebhardt AJ; Rissiek B; Stähler T; Tode N; Khan C; Weisel K; Adam G; Koch-Nolte F; Bannas P
Front Immunol; 2022; 13():1010270. PubMed ID: 36389758
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of gastric cancer around the world.
López MJ; Carbajal J; Alfaro AL; Saravia LG; Zanabria D; Araujo JM; Quispe L; Zevallos A; Buleje JL; Cho CE; Sarmiento M; Pinto JA; Fajardo W
Crit Rev Oncol Hematol; 2023 Jan; 181():103841. PubMed ID: 36240980
[TBL] [Abstract][Full Text] [Related]
14. BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors.
Rigby M; Bennett G; Chen L; Mudd GE; Harrison H; Beswick PJ; Van Rietschoten K; Watcham SM; Scott HS; Brown AN; Park PU; Campbell C; Haines E; Lahdenranta J; Skynner MJ; Jeffrey P; Keen N; Lee K
Mol Cancer Ther; 2022 Dec; 21(12):1747-1756. PubMed ID: 36112771
[TBL] [Abstract][Full Text] [Related]
15. Transient Inhibition of Trastuzumab-Tumor Binding to Overcome the "Binding-Site Barrier" and Improve the Efficacy of a Trastuzumab-Gelonin Immunotoxin.
Chen P; Bordeau BM; Zhang Y; Balthasar JP
Mol Cancer Ther; 2022 Oct; 21(10):1573-1582. PubMed ID: 35930739
[TBL] [Abstract][Full Text] [Related]
16. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.
Martin T; Usmani SZ; Berdeja JG; Agha M; Cohen AD; Hari P; Avigan D; Deol A; Htut M; Lesokhin A; Munshi NC; O'Donnell E; Stewart AK; Schecter JM; Goldberg JD; Jackson CC; Yeh TM; Banerjee A; Allred A; Zudaire E; Deraedt W; Olyslager Y; Zhou C; Pacaud L; Madduri D; Jakubowiak A; Lin Y; Jagannath S
J Clin Oncol; 2023 Feb; 41(6):1265-1274. PubMed ID: 35658469
[TBL] [Abstract][Full Text] [Related]
17. Nanobody-based CAR-T cells for cancer immunotherapy.
Safarzadeh Kozani P; Naseri A; Mirarefin SMJ; Salem F; Nikbakht M; Evazi Bakhshi S; Safarzadeh Kozani P
Biomark Res; 2022 Apr; 10(1):24. PubMed ID: 35468841
[TBL] [Abstract][Full Text] [Related]
18. Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives.
Nicolò E; Giugliano F; Ascione L; Tarantino P; Corti C; Tolaney SM; Cristofanilli M; Curigliano G
Cancer Treat Rev; 2022 May; 106():102395. PubMed ID: 35468539
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
